The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...
A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
INR:1064. haryana cricket team vs chandigarh cricket team match scorecard Novo Nordisk's concizumab subcutaneous i ...
Zacks.com on MSN10d
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County. The Danish drugmaker in 2024 began ...
With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback